Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Ehrig, Klaas ^a   Kilinc, Mehmet O ^b   Chen, Nanhai G ^b,c   Stritzker, Jochen ^a,b   Buckel, Lisa ^a   Zhang, Qian ^b,c   Szalay, Aladar A ^a,b,c,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cancer; Colorectal; Metastasis; Oncolytic virotherapy; Vaccinia virus

Indexed keywords

GAMMA INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; ONCOLYTIC VACCINIA VIRUS GLV 1H68; ONCOLYTIC VIRUS; PROTEIN IP10; RANTES; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; RUC GFP GENE; SINGLE DRUG DOSE; UPREGULATION; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; INJECTIONS, INTRAVENOUS; MACROPHAGES; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINIA VIRUS;

EID: 84875319620     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-79     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Markowitz SD, Dawson DM, Willis J, Willson JK. Focus on colon cancer. Cancer Cell 2002, 1:233-236. 10.1016/S1535-6108(02)00053-3, 12086859.
3. Skibber J, Minksy B, Hoff P. Cancer of the colon. Cancer: Principles and Practice of Oncology 2001, 1216-1271. Philadelphia: Lippincott Williams and Wilkins, DeVita SH V, Rosenberg S.
4. Aghili M, Izadi S, Madani H, Mortazavi H. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol 2010, 6:35-41. 10.1111/j.1743-7563.2010.01275.x, 20398036.
5. Fabrizi E, di Martino S, Pelacchi F, Ricci-Vitiani L. Therapeutic implications of colon cancer stem cells. World J Gastroenterol 2010, 16:3871-3877. 10.3748/wjg.v16.i31.3871, 2923760, 20712047.
6. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007, 254:178-216. 10.1016/j.canlet.2007.02.002, 17383089.
7. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007, 7:133-139. 10.2174/156800907780058862, 17346104.
8. Sturlan S, Stremitzer S, Bauman S, Sachet M, Wolschek M, Ruthsatz T, Egorov A, Bergmann M. Endogenous expression of proteases in colon cancer cells facilitate influenza A viruses mediated oncolysis. Cancer Biol Ther 2010, 10:592-599. 10.4161/cbt.10.6.12565, 20647775.
9. Israelsson S, Jonsson N, Gullberg M, Lindberg AM. Cytolytic replication of echoviruses in colon cancer cell lines. Virol J 2011, 8:473. 10.1186/1743-422X-8-473, 3213228, 21999585.
10. Silver J, Mei YF. Transduction and oncolytic profile of a potent replication-competent adenovirus 11p vector (RCAd11pGFP) in colon carcinoma cells. PLoS One 2011, 6:e17532. 10.1371/journal.pone.0017532, 3063781, 21455297.
11. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008, 16:1637-1642. 10.1038/mt.2008.143, 18628758.
12. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H. Systemic treatment of xenografts with vaccinia virus GLV-1 h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009, 10:301. 10.1186/1471-2164-10-301, 2713268, 19583830.
13. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I. Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1 h68. J Oncol 2010, 2010:736907. 2902752, 20631910.
14. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012, 7:e37239. 10.1371/journal.pone.0037239, 3352892, 22615950.
15. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007, 67:10038-10046. 10.1158/0008-5472.CAN-07-0146, 17942938.
16. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 2007, 142:976-983. discussion 976-983, 10.1016/j.surg.2007.09.017, 18063085.
17. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 2008, 93:4403-4407. 10.1210/jc.2008-0316, 18697871.
18. Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, Lin SF, Chen N, Yu YA, Rusch VW, Szalay AA, Fong Y. Novel oncolytic agent GLV-1 h68 is effective against malignant pleural mesothelioma. Hum Gene Ther 2008, 19:774-782. 10.1089/hum.2008.036, 2940611, 18754710.
19. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1 h68. Mol Cancer Ther 2009, 8:141-151. 10.1158/1535-7163.MCT-08-0533, 2664310, 19139123.
20. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, Raab V, Heisig M, Chen N, Yu YA, Stritzker J, Szalay AA. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1 h68. J Biomed Biotechnol 2010, 2010:489759. 2850154, 20379368.
21. Yu Z, Li S, Brader P, Chen N, Yu YA, Zhang Q, Szalay AA, Fong Y, Wong RJ. Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer 2009, 8:45. 2714037, 19580655.
22. He S, Li P, Chen CH, Bakst RL, Chernichenko N, Yu YA, Chen N, Szalay AA, Yu Z, Fong Y, Wong RJ. Effective oncolytic vaccinia therapy for human sarcomas. J Surg Res 2012, 175:e53-e60. 10.1016/j.jss.2011.11.1030, 22341347.
23. Gentschev I, Muller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1 h68. PLoS One 2011, 6:e22069. 10.1371/journal.pone.0022069, 3133637, 21779374.
24. Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S, Serganova I, Blasberg R, Fong Y, Szalay AA. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med 2009, 15:144-151. 2654849, 19287510.
25. Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mittra A. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med 2011, 9:36. 10.1186/1479-5876-9-36, 3080806, 21453532.
26. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 2009, 106:12915-12920. 10.1073/pnas.0900660106, 2722284, 19617539.
27. Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Cancer Res 2012, 18:2579-2590. 10.1158/1078-0432.CCR-11-2394, 22379115.
28. Pedersen J, Karapanagiotou L, Alam S, Puglisi M, Britton L, Sassi S, Mansfield D, Yap T, De-Bono J, Harrington K. Preliminary results of a Phase I study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging 2010, BT Convention Center, Liverpool, UK: 6th NCRI Cancer Conference.
29. Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1 h68. BMC Cancer 2011, 11:451. 10.1186/1471-2407-11-451, 3213037, 22011439.
30. Miller G, Enders JF. Vaccinia virus replication and cytopathic effect in cultures in phytohemagglutinin-treated human peripheral blood leukocytes. J Virol 1968, 2:787-792. 375692, 5701820.
31. Haga IR, Bowie AG. Evasion of innate immunity by vaccinia virus. Parasitology 2005, 130(Suppl):S11-S25.
32. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007, 4:e353. 10.1371/journal.pmed.0040353, 2222946, 18162040.
33. Parato KA, Lichty BD, Bell JC. Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 2009, 11:13-21.
34. Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009, 58:1355-1362. 10.1007/s00262-009-0686-7, 3404612, 19266198.
35. Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol 2009, 4:527-536. 10.2217/fmb.09.28, 19492964.
36. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007, 96:41-101.
37. Karupiah G, Blanden RV, Ramshaw IA. Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med 1990, 172:1495-1503. 10.1084/jem.172.5.1495, 2188664, 2121889.
38. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993, 177:1809-1814. 10.1084/jem.177.6.1809, 2191047, 8496693.
39. Biragyn A, Longo DL. Neoplastic " Black Ops" : cancer's subversive tactics in overcoming host defenses. Semin Cancer Biol 2012, 22:50-59. 10.1016/j.semcancer.2012.01.005, 3288709, 22257681.
40. Wang H, Chen NG, Minev BR, Szalay AA. Oncolytic vaccinia virus GLV-1 h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med 2012, 10:167. 10.1186/1479-5876-10-167, 3478222, 22901246.